AtriCure Adds Lariat LAA Closure System With $300M SentreHeart Acquisition

AtriCure Inc. has closed a $300m structured deal to acquire SentreHEART Inc., a privately held developer of percutaneous left atrial appendage management solutions.

3d rendering Human Heart

AtriCure Inc. has closed a $300m structured deal to acquire SentreHEART Inc. the privately held developer of the Lariat percutaneous left atrial appendage (LAA) closure device.

AtriCure markets surgical products including the Isolator Synergy Ablation System, the first and only device, either catheter or surgical, to receive FDA approval for the treatment of persistent atrial fibrillation,...

More from Cardiology

More from Device Area